16.26% for Argireline alone) Synergistic effects observed when combined with leuphasyl in dual-peptide formulations Non-inferior to pentapeptide-3 (Vialox) in smoothing expression lines Faster onset of visible effects compared to other topical neuromuscular peptides Molecular Interaction and Receptor Binding Studies Computational Docking and Dynamics Research Advanced in silico studies examined Syn-AKEs binding characteristics to multiple biological targets[3]: SIRT1 binding demonstrated highest affinity (-9.32 kcal/mol) among tested targets Stable binding maintained through 50 nanosecond molecular dynamics simulations Multiple interaction types (hydrogen bonds, salt bridges, pi-stacking) contribute to stability Binding pocket residues identified for potential structure-activity optimization Safety and Cytotoxicity Research Laboratory safety profiling using standard assays established preliminary safety parameters[3]: MTT cytotoxicity assays determined safe concentration ranges for topical formulations Ames genotoxicity testing showed no mutagenic activity at cosmetic use concentrations No sensitization or irritation reported in manufacturer testing (limited independent validation) Some anecdotal reports of skin reactions (redness, itching) in sensitive individuals Formulation and Penetration Research Studies examining topical delivery characteristics revealed[7]: Molecular weight below 500 Da threshold enables effective stratum corneum penetration Compatible with serum, cream, gel, and emulsion formulation bases Maintains stability in pH range 3.0-5.5 typical of cosmetic formulations Optimal use concentrations identified as 0.5-4% for topical applications Critical Research Context: While Syn-AKE has been studied extensively in in vitro systems and limited human topical application trials, comprehensive clinical trials examining long-term safety, optimal dosing, and mechanism validation remain limited

In adult T-cell leukemia/lymphoma (ATLL), ART induced intracellular ROS- and iron-dependent cytotoxicity, which was partly inhibited by treatment with an iron chelator or ferroptosis inhibitor (Yuan et al., 2020
Clark, B
The Jelly texture provides extra full hydration and instant cool and soothing effects all at once
This compound is not approved by the FDA for any use and is supplied strictly for in-vitro laboratory research use only
Journal reference: W